UTMD UTAH MEDICAL PRODUCTS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 706698 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-9.6%
TTM net income YoY-8.4%
TTM EPS YoY-5.6%
Revenue 3-yr CAGR-12.1%
Net income 3-yr CAGR-14.3%
Margins
Gross margin57.7%
Operating margin29.9%
Net margin30.5%
FCF margin31.1%
EBITDA margin32.4%
Returns
ROE8.8%
ROA8.5%
ROIC (approx.)23.7%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets4.1%
Debt / equity0.00x
Current ratio21.23x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.08x
Accruals ratio-0.7%
Payout ratio37.0%
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.62M | $8.53M | $8.72M | $9.04M | $9.81M | $9.95M | $9.71M | $9.16M |
| Cost of revenue | $3.78M | $3.77M | $3.44M | $3.78M | $4.21M | $4.36M | $4.17M | $3.83M |
| Gross profit | $4.84M | $4.76M | $5.28M | $5.26M | $5.60M | $5.59M | $5.54M | $5.32M |
| R&D expense | $142,000 | $154,000 | $154,000 | $212,000 | $167,000 | $135,000 | $154,000 | $121,000 |
| SG&A expense | $1.90M | $1.96M | $2.56M | $560,000 | $2.83M | $2.26M | $2.23M | $371,000 |
| Operating income | $2.79M | $2.65M | $2.56M | $2.44M | $2.61M | $3.20M | $3.15M | $2.93M |
| Pretax income | $3.40M | $3.29M | $3.18M | $3.11M | $3.31M | $3.84M | $3.86M | $3.61M |
| Income tax | $614,000 | $600,000 | $578,000 | $540,000 | $678,000 | $788,000 | $817,000 | $712,000 |
| Net income | $2.79M | $2.69M | $2.60M | $2.56M | $2.63M | $3.05M | $3.04M | $2.90M |
| EBITDA | $3.01M | $2.86M | $2.78M | $2.65M | $2.82M | $3.40M | $3.35M | $3.13M |
| EPS (basic) | 0.88 | 0.84 | 0.82 | — | 0.82 | 0.94 | 0.92 | — |
| EPS (diluted) | 0.88 | 0.84 | 0.82 | 0.80 | 0.82 | 0.94 | 0.92 | 0.86 |
| Weighted avg. shares (diluted) | 3.18M | 3.18M | 3.19M | — | 3.21M | 3.25M | 3.31M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $85.20M | $87.53M | $87.41M | $85.76M | $84.27M | $82.18M | $83.33M | $82.98M |
| Receivables | $3.96M | $3.56M | $3.64M | $3.52M | $3.73M | $3.63M | $3.94M | $4.09M |
| Inventory | $10.57M | $9.00M | $8.72M | $7.93M | $8.12M | $8.23M | $8.65M | $8.81M |
| Current assets | $100.63M | $100.64M | $100.38M | $97.74M | $96.53M | $94.38M | $96.40M | $96.33M |
| PP&E, net | $10.02M | $9.63M | $9.72M | $9.91M | $10.00M | $10.26M | $9.95M | $9.76M |
| Goodwill | $13.96M | $13.96M | $13.92M | $14.05M | $14.05M | $14.19M | $13.77M | $13.58M |
| Intangibles | $3.88M | $346,000 | $364,000 | $840,000 | $1.39M | $1.98M | $2.40M | $2.87M |
| Total assets | $128.50M | $124.57M | $124.38M | $122.54M | $121.97M | $120.80M | $122.52M | $122.54M |
| Current liabilities | $4.74M | $2.07M | $3.50M | $2.60M | $3.01M | $2.25M | $4.32M | $3.76M |
| Long-term debt | $180,000 | $195,000 | $210,000 | $225,000 | — | — | $269,000 | $282,000 |
| Total debt | $180,000 | $195,000 | $210,000 | $225,000 | — | — | $269,000 | $282,000 |
| Total liabilities | $5.22M | $2.54M | $4.01M | $3.27M | $3.72M | $3.27M | $5.47M | $5.11M |
| Shareholders' equity | $123.28M | $122.03M | $120.37M | $119.27M | $118.25M | $117.53M | $117.05M | $117.43M |
| Net debt | -$85.02M | -$87.33M | -$87.20M | -$85.53M | — | — | -$83.06M | -$82.69M |
| Shares outstanding | 3.17M | 3.18M | 3.18M | 3.19M | 3.20M | 3.22M | 3.28M | 3.33M |
| Cash flow statement | ||||||||
| Operating cash flow | $3.50M | $1.38M | $3.11M | $3.48M | $3.88M | $2.87M | $4.46M | $2.94M |
| Capital expenditure | $236,000 | $134,000 | $130,000 | $109,000 | $27,000 | $51,000 | $184,000 | $9,000 |
| Free cash flow | $3.26M | $1.25M | $2.98M | $3.37M | $3.85M | $2.82M | $4.28M | $2.93M |
| Investing cash flow | -$4.28M | -$134,000 | -$130,000 | -$109,000 | -$27,000 | -$51,000 | -$184,000 | -$9,000 |
| Financing cash flow | -$1.58M | -$1.06M | -$1.12M | -$1.97M | -$1.64M | -$4.49M | -$4.24M | -$7.75M |
| Depreciation & amortization | $217,000 | $210,000 | $211,000 | $212,000 | $209,000 | $205,000 | $200,000 | $200,000 |
| Stock-based compensation | $77,000 | $72,000 | $120,000 | $111,000 | $94,000 | $86,000 | $82,000 | $72,000 |
| Dividends paid | $987,000 | $987,000 | $989,000 | $977,000 | $988,000 | $1.00M | $1.02M | $1.04M |
| Share buybacks | $699,000 | $78,000 | $128,000 | $994,000 | $653,000 | $3.49M | $3.22M | $6.71M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.